Literature DB >> 25129490

Biological Modulators in Eosinophilic Diseases.

Panida Sriaroon1, Mark Ballow2.   

Abstract

Eosinophils can regulate local and systemic inflammation, and their presence in higher numbers appears to play an important role in the pathology of various atopic and inflammatory diseases. Eosinophil maturation, recruitment, and survival depend on several cytokine regulators, including interleukin (IL)-5, IL-4, and IL-13 as well as growth factors such as GM-CSF. Over the last decade, the approach to treating eosinophilic diseases has changed greatly. A number of biologic modulators have been developed to target eosinophilic inflammatory pathways, and their usage has resulted in variable clinical improvement in the treatment of eosinophilic-associated conditions. Novel targeted therapies that are safe and effective for treating these disorders are being investigated. This review summarizes the clinical use of biologic agents that have been studied in clinical trials or approved for treating eosinophilic diseases.

Entities:  

Keywords:  Asthma; Biologics; Churg-Strauss syndrome; Eosinophilic diseases; Eosinophilic esophagitis; Eosinophilic granulomatosis with polyangiitis; Eosinophils; Hypereosinophilic syndrome; Monoclonal antibodies; Nasal polyposis

Mesh：

Substances：

Year:  2016        PMID： 25129490     DOI： 10.1007/s12016-014-8444-9

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN： 1080-0549            Impact factor:   8.667


  178 in total

Review 1.  Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.

Authors:  Takumi Kiwamoto; Norihito Kawasaki; James C Paulson; Bruce S Bochner
Journal:  Pharmacol Ther       Date:  2012-06-27       Impact factor: 12.310

2.  Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

Authors:  Jelena V Jovanovic; Joannah Score; Katherine Waghorn; Daniela Cilloni; Enrico Gottardi; Georgia Metzgeroth; Philipp Erben; Helena Popp; Christoph Walz; Andreas Hochhaus; Catherine Roche-Lestienne; Claude Preudhomme; Ellen Solomon; Jane Apperley; Michela Rondoni; Emanuela Ottaviani; Giovanni Martinelli; Finella Brito-Babapulle; Giuseppe Saglio; Rüdiger Hehlmann; Nicholas C P Cross; Andreas Reiter; David Grimwade
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113

Review 3.  Eosinophilic esophagitis: updated consensus recommendations for children and adults.

Authors:  Chris A Liacouras; Glenn T Furuta; Ikuo Hirano; Dan Atkins; Stephen E Attwood; Peter A Bonis; A Wesley Burks; Mirna Chehade; Margaret H Collins; Evan S Dellon; Ranjan Dohil; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; David A Katzka; Alfredo J Lucendo; Jonathan E Markowitz; Richard J Noel; Robert D Odze; Philip E Putnam; Joel E Richter; Yvonne Romero; Eduardo Ruchelli; Hugh A Sampson; Alain Schoepfer; Nicholas J Shaheen; Scott H Sicherer; Stuart Spechler; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Marc E Rothenberg; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2011-04-07       Impact factor: 10.793

4.  An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro.

Authors:  Hiromi Sugimoto; Michitaka Shichijo; Takashi Iino; Yoshihisa Manabe; Akihiko Watanabe; Makoto Shimazaki; Florian Gantner; Kevin B Bacon
Journal:  J Pharmacol Exp Ther       Date:  2003-04       Impact factor: 4.030

5.  The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.

Authors:  Michele Baccarani; Daniela Cilloni; Michela Rondoni; Emanuela Ottaviani; Francesca Messa; Serena Merante; Mario Tiribelli; Francesco Buccisano; Nicoletta Testoni; Enrico Gottardi; Antonio de Vivo; Emilia Giugliano; Ilaria Iacobucci; Stefania Paolini; Simona Soverini; Gianantonio Rosti; Francesca Rancati; Cinzia Astolfi; Fabrizio Pane; Giuseppe Saglio; Giovanni Martinelli
Journal:  Haematologica       Date:  2007-08-01       Impact factor: 9.941

6.  Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.

Authors:  Srdan Verstovsek; Ayalew Tefferi; Hagop Kantarjian; Taghi Manshouri; Raja Luthra; Animesh Pardanani; Alfonso Quintás-Cardama; Farhad Ravandi; Pat Ault; Carlos Bueso-Ramos; Jorge E Cortes
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

7.  The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma.

Authors:  G-J Braunstahl; C-W Chen; R Maykut; P Georgiou; G Peachey; J Bruce
Journal:  Respir Med       Date:  2013-05-28       Impact factor: 3.415

8.  Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.

Authors:  Michael Noonan; Phillip Korenblat; Sofia Mosesova; Heleen Scheerens; Joseph R Arron; Yanan Zheng; Wendy S Putnam; Merdad V Parsey; Sean P Bohen; John G Matthews
Journal:  J Allergy Clin Immunol       Date:  2013-05-29       Impact factor: 10.793

Review 9.  Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence.

Authors:  Kalliopi Tanou; Elias Zintzaras; Athanasios G Kaditis
Journal:  Pediatr Pulmonol       Date:  2013-10-25

10.  A novel antagonist of CRTH2 blocks eosinophil release from bone marrow, chemotaxis and respiratory burst.

Authors:  J F Royer; P Schratl; S Lorenz; E Kostenis; T Ulven; R Schuligoi; B A Peskar; A Heinemann
Journal:  Allergy       Date:  2007-08-21       Impact factor: 13.146
View more
  5 in total

Review 1.  Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review.

Authors:  Loïc Raffray; Loïc Guillevin
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

Review 2.  The Eosinophil in Health and Disease: from Bench to Bedside and Back.

Authors:  Wei Liao; Hai Long; Christopher Chia-Chi Chang; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 8.667

3.  Eosinophil Count Is a Common Factor for Complex Metabolic and Pulmonary Traits and Diseases: The LifeLines Cohort Study.

Authors:  Marzyeh Amini; Dinara Bashirova; Bram P Prins; Eva Corpeleijn; Marcel Bruinenberg; Lude Franke; Pim van der Harst; Gerjan Navis; Bruce H R Wolffenbuttel; Ronald P Stolk; Cisca Wijmenga; Dirkje S Postma; Gerard H Koppelman; H Marike Boezen; Judith Vonk; Harold Snieder; Behrooz Z Alizadeh
Journal:  PLoS One       Date:  2016-12-15       Impact factor: 3.240

4.  Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis.

Authors:  Lynn D Condreay; Laura R Parham; Xiaoyan A Qu; Jonathan Steinfeld; Michael E Wechsler; Benjamin A Raby; Steven W Yancey; Soumitra Ghosh
Journal:  Rheumatol Int       Date:  2020-02-03       Impact factor: 2.631

Review 5.  More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis.

Authors:  Martha Gschwandtner; Rupert Derler; Kim S Midwood
Journal:  Front Immunol       Date:  2019-12-13       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.